Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics, Inc. (TENX) — VMCI valuation read

Composite valuation read on TENX: VMCI 35/100 against a Healthcare sector median of 50. The 15-point below-median print is the headline number for Tenax Therapeutics, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for TENX: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on TENX: TENX trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of -0.7x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

TENX fell 1.5% over the trailing 7 days, with a -0.7% read on a 30-day basis.